Kirkland Represents Bristol-Myers Squibb on Acquisition of Cormorant Pharmaceuticals for up to $520 Million

Kirkland & Ellis LLP advised Bristol-Myers Squibb Co. (NYSE: BMY), a global biopharmaceutical company, on the acquisition of the outstanding capital stock of Cormorant Pharmaceuticals, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The total value of the transaction is $520 million dependent on contingencies. The full release is available here.

The Kirkland team was led by corporate partners Daniel Wolf, Joshua Zachariah and associate Patrick Jacobs; and technology and intellectual property transactions partner Lisa Samenfeld.